
S173: T‐CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T‐CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Author(s) -
Dekhtiarenko I.,
Lelios I.,
Attig J.,
Sleiman N.,
Lazzaro D.,
Clausen I.,
Gräfe N.,
Helms H.J.,
Schindler E.,
Belli S.,
Fauti T.,
Eckmann J.,
Umana P.,
Jacob W.,
Schneider M.,
Hasselbalch Riley C.,
Hutchings M.,
Yoon S.S.,
Koh Y,
Manier S.,
Facon T.,
Harrison S. J.,
Er J.,
Volzone F.,
Pinto A.,
Montes C.,
Ocio E. M.,
AlfonsoPierola A.,
Rodríguez Otero P.,
Offner F.,
Guidetti A.,
Corradini P.,
Titouan C.,
Hulin C.,
Touzeau C.,
Moreau P.,
Popat R.,
Leong S.,
Mazza R.,
CarloStella C.,
Bröske A.M. E.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843584.56113.c6
Subject(s) - medicine , cd8 , pharmacodynamics , t cell , multiple myeloma , cytokine release syndrome , flow cytometry , pharmacology , antibody , bone marrow , biomarker , oncology , pharmacokinetics , immune system , immunology , chemistry , chimeric antigen receptor , biochemistry